Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol as add-on in early schizophrenia (CBD-ESPRIT)
NCT02926859Phase 2Active, not recruiting
- Sponsor
- Central Institute of Mental Health
- Start
- Apr 2017
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in schizophrenia, sponsored by Central Institute of Mental Health. Started Apr 2017; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02926859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926859.